Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir + amibufenamide
- Development stage
- Phase 4
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tenofovir + amibufenamide is a fixed-dose combination of two antiviral agents used for the treatment of hepatitis B virus (HBV) infection. Tenofovir, typically in the form of tenofovir disoproxil fumarate or tenofovir alafenamide, is a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits viral replication by incorporating into viral DNA and causing chain termination. Amibufenamide (also known as E-CFCP) is a novel nucleoside analog reverse transcriptase inhibitor developed to provide potent anti-HBV activity with improved safety and pharmacokinetics compared to existing therapies. The combination aims to enhance antiviral efficacy while minimizing toxicity, particularly renal and bone side effects associated with older formulations of tenofovir.
- Brand names
- Hengmu
- Other names
- tenofovir amibufenamide fumarate
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tenofovir + amibufenamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir + amibufenamide.